XERS Xeris Biopharma Holdings, Inc.

NEUTRAL Impact: 2/10 144
Horizon immediate Filed Jun 3, 2026 Processed 1d 12h ago SEC 0001950047-26-005565
Form 144 — notice of proposed sale of securities
Latest settled — T+1d
XERS ▲ +0.49% at T+1d
NEUTRAL call ✓ call won +0.49% · α vs SPY +3.06% · entry $6.15 → $6.18
Next anchor: T+5d in 4d
Currently $6.18 · +0.49% from $6.15 entry
Entry anchored
Jun 3, 03:59 PM ET
via Databento tick
T+1d
+0.49%
call +0.49% · α +3.06%
$6.18
settled 2d ago
T+5d
call — · α —
in 4d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Director Marla Persky filed a Form 144 notice of intent to sell 15,500 shares of XERS common stock, with an estimated aggregate market value of $93,000. The shares were acquired via restricted stock units on June 3, 2026. This is a small, routine sale by a non-executive director — the dollar value is negligible relative to the company's $1.1B market cap and represents no material insider signal.

Actionable Insight

This is a de minimis proposed sale by a director. No actionable signal for traders — the filing is routine and carries no material information about company fundamentals or insider sentiment. Monitor for any larger insider sales ahead of next earnings.

Key Facts

  • Filer: Director Marla Persky (non-executive board member)
  • Shares to be sold: 15,500 shares of common stock
  • Estimated value: $93,000 (based on filing date price of ~$6.00/share)
  • Shares acquired via restricted stock units on June 3, 2026
  • Sale intended to be executed through Morgan Stanley Smith Barney
  • Market cap of XERS: ~$1.1B — sale represents ~0.008% of market cap
  • Recent insider activity (30d): 1 prior sell totaling $101K

Financial Impact

Proposed sale of $93,000 in stock by a director — immaterial relative to $1.1B market cap

dilution

Risk Factors

  • No material risk identified from this filing alone

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005565
Document: 0001950047-26-005565-index.html0001950047-26-005565
Document: 0001950047-26-005565.txt0001950047-26-005565
5 reports for XERS
Performance horizon
Filters
Rows
Reports for XERS — sortable, filterable
Type Now
Jun 5, 2026
1d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
Jun 5, 2026
1d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+1
Jun 4, 2026
2d ago
144
NEUTRAL ★ 2/10
awaiting T+1
Jun 3, 2026
3d ago
144
NEUTRAL ★ 2/10
$6.15 $6.18▲ +0.49%▲ +3.06%$6.18 (+0.49%)
Feb 27, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$6.12 $6.02▼ −1.63%▼ −1.69%$6.18 (+0.98%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (14h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access